These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26126090)

  • 1. Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
    Horie S
    Kidney Int; 2015 Jul; 88(1):14-6. PubMed ID: 26126090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
    Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
    Bhutani H; Smith V; Rahbari-Oskoui F; Mittal A; Grantham JJ; Torres VE; Mrug M; Bae KT; Wu Z; Ge Y; Landslittel D; Gibbs P; O'Neill WC; Chapman AB;
    Kidney Int; 2015 Jul; 88(1):146-51. PubMed ID: 25830764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression.
    Furlano M; Loscos I; Martí T; Bullich G; Ayasreh N; Rius A; Roca L; Ballarín J; Ars E; Torra R
    Am J Nephrol; 2018; 48(4):308-317. PubMed ID: 30347391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
    D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH
    Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Iijima H; Tada T; Hashimoto M; Nishimura T; Kiriki M; Higashiura A; Iwasaki A; Honda M; Nagasawa Y; Yamakado K
    J Med Ultrason (2001); 2023 Jan; 50(1):81-87. PubMed ID: 36333536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
    Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
    Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease.
    Demiray A; Ozan R; Özaytürk SG; İmamoğlu H; Zararsız G; Sipahioğlu MH; Tokgöz B; Elçik D; Koçyiğit İ
    Cardiorenal Med; 2024; 14(1):167-177. PubMed ID: 38423003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.
    Rodríguez RM; Luis-Lima S; Fernandez JM; Gómez MVP; Toledo BG; Cobo M; Delgado-Mallén P; Escamilla B; Marco CO; Estupiñán S; Perera CC; Mena NN; Martín LD; Reyes SP; González IH; González-Rinne F; González-Delgado A; Ferrer-Moure C; Zulueta BL; Torres A; Rodriguez Pérez JC; Gaspari F; Ortiz A; Porrini E
    J Nephrol; 2022 Nov; 35(8):2109-2118. PubMed ID: 35357684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
    Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
    J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.